<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02305758</url>
  </required_header>
  <id_info>
    <org_study_id>M14-217</org_study_id>
    <secondary_id>2014-002866-65</secondary_id>
    <nct_id>NCT02305758</nct_id>
  </id_info>
  <brief_title>Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer</brief_title>
  <official_title>Randomized, Blinded, Multicenter, Phase 2 Study Comparing Veliparib Plus FOLFIRI ± Bevacizumab Versus Placebo Plus FOLFIRI ± Bevacizumab in Previously Untreated Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to evaluate the efficacy and tolerability of veliparib in combination with
      FOLFIRI +/- bevacizumab in previously untreated, metastatic adenocarcinoma of the colon or
      rectum. FOLFIRI is a chemotherapy regimen of fluorouracil, leucovorin and irinotecan.

      This is a blinded study such that the Investigator and Subject will be blinded but AbbVie
      will be unblinded.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2, 2014</start_date>
  <completion_date type="Actual">September 22, 2017</completion_date>
  <primary_completion_date type="Actual">September 22, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 3 years from the first subject dosed.</time_frame>
    <description>The number of days from the date the participant is randomized to the date the participant experiences a disease progression event or to the date of death if disease progression is not reached.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 3 years from the first subject dosed.</time_frame>
    <description>Overall survival is defined as the number of days from the date that the participant was randomized to the date of the participant's death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 3 years from the first subject dosed.</time_frame>
    <description>The proportion of participants with a complete or partial objective response based on Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Untreated Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo plus FOLFIRI with or without bevacizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Veliparib plus modified FOLFIRI with or without bevacizumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Veliparib</intervention_name>
    <description>Veliparib will be given for 7 days of the 14 day cycle. One treatment of FOLFIRI with or without bevacizumab will be given during the 14 day cycle.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be given for 7 days of the 14 day cycle. One treatment of FOLFIRI with or without bevacizumab will be given during the 14 day cycle.</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed metastatic adenocarcinoma of the colon or
             rectum

          -  At least 1 unresectable lesion on a CT (Computerized Tomography) scan that is
             measurable as defined by RECIST, Version 1.1

          -  ECOG (Eastern Cooperative Oncology Group) performance score of 0 or 1

          -  Adequate hematologic, renal and hepatic function

        Exclusion Criteria:

          -  Prior anti-cancer treatment for metastatic colorectal cancer

          -  Prior exposure to PARP (poly ADP-ribose polymerase) inhibitors

          -  The last course of adjuvant or neoadjuvant chemotherapy must have ended &gt; 12 months
             prior to colorectal cancer recurrence

          -  Any clinically significant and uncontrolled major medical condition

          -  Participant is pregnant or lactating

          -  Any medical condition, which in the opinion of the study Investigator, places the
             participant at an unacceptably high risk for toxicities

          -  For those receiving bevacizumab, standard medical exclusionary conditions apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2014</study_first_submitted>
  <study_first_submitted_qc>December 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2014</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PARP inhibitor</keyword>
  <keyword>veliparib</keyword>
  <keyword>metastatic colorectal cancer</keyword>
  <keyword>ABT-888</keyword>
  <keyword>first line</keyword>
  <keyword>previously untreated</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>colon cancer</keyword>
  <keyword>rectal cancer</keyword>
  <keyword>FOLFIRI</keyword>
  <keyword>fluorouracil</keyword>
  <keyword>5-FU</keyword>
  <keyword>leucovorin</keyword>
  <keyword>irinotecan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Veliparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

